NCT02047175View on ClinicalTrials.gov

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
HypertensionHyperlipidemia
Interventions
DRUG

Telmisartan/S-Amlodipine

Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days

DRUG

Rosuvastatin

Rosuvastatin 20mg 1T PO, QD for 5days

DRUG

Telmisartan/S-Amlodipine + Rosuvastatin

Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days

DRUG

Telmisartan/S-Amlodipine + Rosuvastatin

Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days

Trial Locations (1)

Unknown

The catholic university of Korea, seoul ST.Mary's hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY